411 related articles for article (PubMed ID: 20634376)
1. CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice.
Martelli MP; Pettirossi V; Thiede C; Bonifacio E; Mezzasoma F; Cecchini D; Pacini R; Tabarrini A; Ciurnelli R; Gionfriddo I; Manes N; Rossi R; Giunchi L; Oelschlägel U; Brunetti L; Gemei M; Delia M; Specchia G; Liso A; Di Ianni M; Di Raimondo F; Falzetti F; Del Vecchio L; Martelli MF; Falini B
Blood; 2010 Nov; 116(19):3907-22. PubMed ID: 20634376
[TBL] [Abstract][Full Text] [Related]
2. Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction.
Taussig DC; Vargaftig J; Miraki-Moud F; Griessinger E; Sharrock K; Luke T; Lillington D; Oakervee H; Cavenagh J; Agrawal SG; Lister TA; Gribben JG; Bonnet D
Blood; 2010 Mar; 115(10):1976-84. PubMed ID: 20053758
[TBL] [Abstract][Full Text] [Related]
3. AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features.
Haferlach C; Mecucci C; Schnittger S; Kohlmann A; Mancini M; Cuneo A; Testoni N; Rege-Cambrin G; Santucci A; Vignetti M; Fazi P; Martelli MP; Haferlach T; Falini B
Blood; 2009 Oct; 114(14):3024-32. PubMed ID: 19429869
[TBL] [Abstract][Full Text] [Related]
4. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?
Falini B; Martelli MP; Bolli N; Sportoletti P; Liso A; Tiacci E; Haferlach T
Blood; 2011 Jan; 117(4):1109-20. PubMed ID: 21030560
[TBL] [Abstract][Full Text] [Related]
5. The absent/low expression of CD34 in NPM1-mutated AML is not related to cytoplasmic dislocation of NPM1 mutant protein.
Pianigiani G; Rocchio F; Peruzzi S; Andresen V; Bigerna B; Sorcini D; Capurro M; Gjertsen BT; Sportoletti P; Di Ianni M; Martelli MP; Brunetti L; Falini B
Leukemia; 2022 Jul; 36(7):1931-1934. PubMed ID: 35568767
[No Abstract] [Full Text] [Related]
6. A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia.
Angelini DF; Ottone T; Guerrera G; Lavorgna S; Cittadini M; Buccisano F; De Bardi M; Gargano F; Maurillo L; Divona M; Noguera NI; Consalvo MI; Borsellino G; Bernardi G; Amadori S; Venditti A; Battistini L; Lo-Coco F
Clin Cancer Res; 2015 Sep; 21(17):3977-85. PubMed ID: 25957287
[TBL] [Abstract][Full Text] [Related]
7. Nucleophosmin mutation in de-novo acute myeloid leukemia.
Rastogi P; Naseem S; Varma N; Varma S
Asia Pac J Clin Oncol; 2016 Mar; 12(1):77-85. PubMed ID: 26669619
[TBL] [Abstract][Full Text] [Related]
8. Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones.
Al-Mawali A; Gillis D; Lewis I
J Hematol Oncol; 2016 Jul; 9(1):61. PubMed ID: 27465508
[TBL] [Abstract][Full Text] [Related]
9. The complement receptor C3AR constitutes a novel therapeutic target in NPM1-mutated AML.
von Palffy S; Thorsson H; Peña-Martínez P; Puente-Moncada N; Sandén C; Blom AM; Henningsson R; Juliusson G; King B; Landberg N; Lazarevic V; Orsmark-Pietras C; Rissler M; Rissler V; Ågerstam H; Järås M; Lilljebjörn H; Fioretos T
Blood Adv; 2023 Apr; 7(7):1204-1218. PubMed ID: 36383712
[TBL] [Abstract][Full Text] [Related]
10. CD34+CD38-CD123+ Cells Are Present in Virtually All Acute Myeloid Leukaemia Blasts: A Promising Single Unique Phenotype for Minimal Residual Disease Detection.
Al-Mawali A; Pinto AD; Al-Zadjali S
Acta Haematol; 2017; 138(3):175-181. PubMed ID: 29065396
[TBL] [Abstract][Full Text] [Related]
11. Imidazoquinoxaline derivative EAPB0503: A promising drug targeting mutant nucleophosmin 1 in acute myeloid leukemia.
Nabbouh AI; Hleihel RS; Saliba JL; Karam MM; Hamie MH; Wu HJM; Berthier CP; Tawil NM; Bonnet PA; Deleuze-Masquefa C; El Hajj HA
Cancer; 2017 May; 123(9):1662-1673. PubMed ID: 28055106
[TBL] [Abstract][Full Text] [Related]
12. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications.
Falini B; Bolli N; Liso A; Martelli MP; Mannucci R; Pileri S; Nicoletti I
Leukemia; 2009 Oct; 23(10):1731-43. PubMed ID: 19516275
[TBL] [Abstract][Full Text] [Related]
13. CD45
Heo SK; Noh EK; Ju LJ; Sung JY; Jeong YK; Cheon J; Koh SJ; Min YJ; Choi Y; Jo JC
BMC Cancer; 2020 Apr; 20(1):285. PubMed ID: 32252668
[TBL] [Abstract][Full Text] [Related]
14. Acute myeloid leukemia with mutated NPM1 mimics acute promyelocytic leukemia presentation.
Arana Rosainz MJ; Nguyen N; Wahed A; Lelenwa LC; Aakash N; Schaefer K; Rios A; Kanaan Z; Chen L
Int J Lab Hematol; 2021 Apr; 43(2):218-226. PubMed ID: 33099879
[TBL] [Abstract][Full Text] [Related]
15. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin.
Garzon R; Garofalo M; Martelli MP; Briesewitz R; Wang L; Fernandez-Cymering C; Volinia S; Liu CG; Schnittger S; Haferlach T; Liso A; Diverio D; Mancini M; Meloni G; Foa R; Martelli MF; Mecucci C; Croce CM; Falini B
Proc Natl Acad Sci U S A; 2008 Mar; 105(10):3945-50. PubMed ID: 18308931
[TBL] [Abstract][Full Text] [Related]
16. [Immunophenotypic and clinical characteristic analysis of NPM1 mutated acute myeloid leukemia with a normal karyotype].
Liu YR; Lai YY; Chang Y; Ruan GR; Qin YZ; Wang YZ; Zhu HH; Shi HX; Jiang B; Jiang H; Jiang Q; Hao L; Li JL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1385-9. PubMed ID: 24370016
[TBL] [Abstract][Full Text] [Related]
17. Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML.
Herrmann H; Blatt K; Shi J; Gleixner KV; Cerny-Reiterer S; Müllauer L; Vakoc CR; Sperr WR; Horny HP; Bradner JE; Zuber J; Valent P
Oncotarget; 2012 Dec; 3(12):1588-99. PubMed ID: 23249862
[TBL] [Abstract][Full Text] [Related]
18. Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells.
Martelli MP; Gionfriddo I; Mezzasoma F; Milano F; Pierangeli S; Mulas F; Pacini R; Tabarrini A; Pettirossi V; Rossi R; Vetro C; Brunetti L; Sportoletti P; Tiacci E; Di Raimondo F; Falini B
Blood; 2015 May; 125(22):3455-65. PubMed ID: 25795919
[TBL] [Abstract][Full Text] [Related]
19. Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1).
Falini B; Macijewski K; Weiss T; Bacher U; Schnittger S; Kern W; Kohlmann A; Klein HU; Vignetti M; Piciocchi A; Fazi P; Martelli MP; Vitale A; Pileri S; Miesner M; Santucci A; Haferlach C; Mandelli F; Haferlach T
Blood; 2010 May; 115(18):3776-86. PubMed ID: 20203266
[TBL] [Abstract][Full Text] [Related]
20. Mutant NPM1-regulated lncRNA HOTAIRM1 promotes leukemia cell autophagy and proliferation by targeting EGR1 and ULK3.
Jing Y; Jiang X; Lei L; Peng M; Ren J; Xiao Q; Tao Y; Tao Y; Huang J; Wang L; Tang Y; Yang Z; Yang Z; Zhang L
J Exp Clin Cancer Res; 2021 Oct; 40(1):312. PubMed ID: 34615546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
